Comparative Pharmacology
Head-to-head clinical analysis: DYANAVEL XR 5 versus QUILLIVANT XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYANAVEL XR 5 versus QUILLIVANT XR.
DYANAVEL XR 5 vs QUILLIVANT XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CNS stimulant; blocks reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their synaptic concentrations.
Extended-release oral suspension formulation of methylphenidate, a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their synaptic concentrations. The exact therapeutic effect in ADHD is unknown but is thought to involve dopaminergic and noradrenergic pathways in the prefrontal cortex.
20 mg orally once daily in the morning; may increase by 10 mg weekly based on response; maximum 60 mg/day.
Initial: 25 mg orally once daily in the morning; may increase weekly in 25 mg increments based on tolerability and response. Maximum: 75 mg once daily.
None Documented
None Documented
Terminal elimination half-life for d-amphetamine is 10-13 hours; for l-amphetamine, 13-16 hours. Clinical context: Twice-daily dosing may be required for sustained effect.
Approximately 4 hours; extended-release formulation provides therapeutic levels for ~12 hours.
Renal: ~90% as unchanged amphetamine and metabolites. Fecal: minimal (<5%).
Primarily renal (approximately 60% as unchanged drug); fecal excretion accounts for <5%.
Category C
Category C
CNS Stimulant
CNS Stimulant